Peter Rothschild, President of BioGaia, summarises the first quarter of 2015 and answers questions regarding;
- main reasons to strong results in first quarter,
- the Brasilian market and its future,
- agreement with Nestlé regarding development of new products,
- the BioGaia subsidary IBT (Infant Bacterial Therapeutics) and its NEC-project,
- and the new agreement in Mexico regarding sales of Oral Health tablets